Trial Profile
An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 14 Mar 2013 New trial record
- 08 Mar 2013 Status changed from active, no longer recruiting to completed.